Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lovaza in Acute Inflammation Blister Model
NCT04308889Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid in acute inflammation (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Specialized Pro-Resolving Mediators in Acute Inflammation at 24 hours. Started Jul 2018; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
acute inflammation
Beyond the preview
Go deeper on NCT04308889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308889.